Furthermore, as in primary cells UCN-01 sensitivity is strictly related to the integrity of the p53 sequence, we hypothesize that the combination of IO and a Chk1 inhibitor could greatly benefit patients affected by r/r B-ALL displaying mutant p53. Here, CHEK1 is linked to acute lymphoblastic leukemia.